Affimed NV (NASDAQ:AFMD) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 4,200,000 shares, a decline of 16.5% from the August 15th total of 5,030,000 shares. Based on an average daily trading volume, of 1,440,000 shares, the short-interest ratio is presently 2.9 days.
Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Affimed from a “sell” rating to a “hold” rating in a research note on Friday, August 21st. SVB Leerink lifted their price objective on shares of Affimed from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 24th. Laidlaw reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Sunday, August 9th. Finally, Zacks Investment Research downgraded shares of Affimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 1st. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $7.67.
NASDAQ AFMD opened at $3.55 on Thursday. The company has a market capitalization of $270.65 million, a PE ratio of -5.07 and a beta of 2.47. The company has a fifty day moving average of $3.58 and a 200 day moving average of $3.03. Affimed has a 1 year low of $1.42 and a 1 year high of $4.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.93 and a quick ratio of 2.91.
Affimed (NASDAQ:AFMD) last posted its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The business had revenue of $3.23 million for the quarter, compared to analyst estimates of $6.79 million. Affimed had a negative net margin of 315.16% and a negative return on equity of 133.60%. Research analysts expect that Affimed will post -0.49 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of AFMD. SG Americas Securities LLC acquired a new position in Affimed during the first quarter valued at $48,000. Bank of New York Mellon Corp increased its holdings in Affimed by 3.4% in the first quarter. Bank of New York Mellon Corp now owns 161,437 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 5,294 shares in the last quarter. State Street Corp increased its holdings in Affimed by 6.9% in the first quarter. State Street Corp now owns 1,190,695 shares of the biopharmaceutical company’s stock valued at $1,881,000 after buying an additional 76,878 shares in the last quarter. GSA Capital Partners LLP increased its holdings in Affimed by 110.6% in the first quarter. GSA Capital Partners LLP now owns 23,226 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,196 shares in the last quarter. Finally, Citigroup Inc. increased its holdings in Affimed by 25.6% in the first quarter. Citigroup Inc. now owns 25,917 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 5,285 shares in the last quarter. Institutional investors own 64.19% of the company’s stock.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Recommended Story: Learning About the VIX – Volatility Index
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.